In a CD19-B16 melanoma mouse model, mice receiving both vancomycin and CD19-targeted CAR T-cells (CART-19) demonstrated superior tumor control and increased tumor-associated antigen (TAA) cross-presentation than those treated with CART-19 alone. Here, CD19 is linked to melanoma.